Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
PHASE1
The primary objective of the Phase Ib study is to determine the dose-limiti...
Status
Withdrawn
Location
The University of Texas M.D. Anderson Cancer Center